Blocknomi
TLDR Capricor Therapeutics stock stays flat at $6.57 after Lancet publishes HOPE-3 data. The Lancet’s peer review confirms Deramiocel’s Phase 3 trial design and results. UC Davis expert calls HOPE-3…
Related articles
-
CLARITY Act Has Two Weeks to Clear the Senate — Or Risk Getting Lost in Midterm Politics
Bitcoin.com Published 25.07.2026 03:30
-
Fairshake, $48M, and the Senate Vote Ripple Is Racing to Win
Cryptonews Published 28.07.2026 12:35
-
What is a tokenized deposit? Bank money goes on-chain
Crypto.News Published 20.07.2026 14:18
-
Kalshi, Polymarket open interest falls 20% as World Cup frenzy winds down
The Block Published 20.07.2026 21:12
-
Bitcoin (BTC) Surges Past $65,500 as Spot ETF Inflows Continue for Fifth Consecutive Day
Blocknomi Published 21.07.2026 06:51
-
Swan CEO claims Twenty One serves Tether’s US political interests, calls Mallers’ role ‘ceremonial’
The Block Published 23.07.2026 16:31
-
Tom Lee Warns Ethereum Will Penalize Impatient Investors as Deleveraging Shifts Capital to Yield
BlockchainReporter Published 18.07.2026 12:00
-
XRP Price Stalls Despite Huge Weekly ETF Net Inflows
Cryptonews Published 27.07.2026 10:02